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ABSTRACT
The survivors of childhood cancers are often associated with adverse late effects
including hypoplasia, fatigue, and infertility, which are characteristics of aging. However,
the underlying mechanisms of the late effects of chemotherapy are still elusive. We have
found that transgenic cyclooxygenase-2 (COX2) expression causes premature aging
phenotypes. Since COX2 expression is highly induced by various chemotherapeutic
agents, we further investigated the possible link between COX2 and the late effects of
chemotherapy. Treatment of juvenile wild-type mice with doxorubicin (DOX), an
anthracycline-based chemotherapeutic agent, resulted in premature aging phenotypes and
escalated cellular senescence level in various tissues. We found that tissue expression of
COX2 persists even 11 weeks after cessation of DOX treatment. Moreover, COX
inhibitors successfully alleviated cellular senescence level and early aging phenotypes in
DOX-treated mice. In addition, genetic deletion or pharmacological inhibition of COX2
in cell lines significantly decreased DOX-induced cellular senescence. Also, treatment
with COX inhibitors induced cell death among senescent cells, possibly through
inhibition of p70 and Bcl signaling, consistent with our in vivo observation. Our results
indicate that chemotherapy-induced COX2 may play an important role in the late effects
of chemotherapy. COX inhibitors, which have been used in medical treatments for
centuries, could serve as senolytic drugs by eliminating senescent cells to restore
homeostasis and rescue aging phenotypes.
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CHAPTER 1
INTRODUCTION
1.1 AGING AND LATE EFFECTS OF CHILDHOOD CANCER SURVIVORS
Aging is characterized by a steady decline in organ function, leading to the loss of
physiologic reserve and frailty (Sanoff, Deal et al. 2014). Healthy aging is a process of
adaptation to the changes of life, which allows elderly individuals to maintain their
physical, mental, and social wellbeing (Lipshultz, Lipsitz et al. 2002). Growing evidence
suggests that environmental factors play an important role in aging. A large number of
mouse models to study mechanisms of aging have been developed, including models
with mutation in genes responsible for reactive oxygen species (ROS) scavenging (Sod2),
cell cycle check point components (AIMP3, Atm, Bub/b, p16, Trp53), DNA repair and
maintenance (Ercc, Polg, Prkdc, Terc, Wrm, Xrcc5, Rag1), nuclear mechanical properties
(Luna, Zmpste 24), and components in signaling pathways of Wnt or calcium-phosphate
metabolism (Gsk3a, Kl, and Fgf23) (Harkema, Youssef et al. 2016). Although these
models are valuable to study the effect of genetic mutation on aging, they are not
applicable for analysis of environmental effects on aging.
Cancer is the second commonest cause of death in children in developed
countries, and childhood cancer and its treatment have remained a challenge for patients,
their families, and oncologists (Kaatsch 2010). Survivors of childhood cancer are
expected to live decades of post-cancer life. However, adult survivors of childhood
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cancers are known to be at risk for chemotherapy-related adverse health outcomes
(Hudson, Ness et al. 2013), resembling aging phenotypes. They should receive optimum
care to reduce the consequences of late effects, including second malignancies, organ
dysfunction, premature skin and ocular changes, early onset of frailty, endocrine and
metabolic disorders, and cognitive and psychosocial problems, which may emerge many
years, even decades, after completion of treatment (Maccormick 2006, Kremer, Mulder et
al. 2013). While an accumulating body of evidence supports the hypothesis that cancer
treatment is associated with accelerated aging, the mechanisms that lead to a functional
decline or frailty remain elusive. Additionally, while the mouse models of cancer include
both genetic and chemically-induced models, there are no chemically-induced mouse
models of aging. There is also the lack of a mouse model that can be used to study the
late effects of chemotherapy.
1.2 DOXORUBICIN
The anthracyclines, including doxorubicin (DOX), are among the most widely
used and successful chemotherapeutics for childhood cancers. DOX has been used in
oncologic treatment since the 1960s. It exerts its effect by intercalating DNA to inhibit
the progression of topoisomerase II, an enzyme which relaxes supercoils in DNA, and by
generating ROS, which can cause oxidative stress and result in significant damage to cell
structures (Bartlett, Trivedi et al. 2017). When it is given as single agent or in
combination with other antitumor agents, the tumors most commonly responding to DOX
include breast and esophageal carcinomas, osteosarcoma, Kaposi’s sarcoma, soft-tissue
sarcomas, and Hodgkin’s and non-Hodgkin’s lymphomas (Singal and Iliskovic 1998).
Sarcomas and lymphoblastic leukemia, common cancers in children, have been treated
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with DOX for many years (Lipshultz, Colan et al. 1991, Lipshultz, Lipsitz et al. 1995).
Also, between 1972 and 1987, children with acute lymphoblastic leukemia were treated
with different doses of DOX protocols (Lipshultz, Lipsitz et al. 1995). In addition, it is
reported that children treated with anthracyclines are at increased risk for various
complications (Hudson, Mertens et al. 2003, Alvarez, Scully et al. 2007, Mody, Li et al.
2008, Miller, Lipsitz et al. 2010, Harake, Franco et al. 2012). DOX is frequently
associated with late effects including cachexia and cardiomyopathy (Bartlett, Trivedi et
al. 2017), and DOX has been shown to induce senescence in both humans and mice
(Sanoff, Deal et al. 2014, Demaria, O'Leary et al. 2016, Baar, Brandt et al. 2017).
However, the mechanism behind senescence and late effects of DOX is still largely
unknown.
1.3 CELLULAR SENESCENCE
Cellular senescence is a state of irreversible growth arrest, and can be triggered by
multiple mechanisms including telomere shortening, the DNA damage, and the
epigenetic derepression of the INK4a/ARF locus (Collado, Blasco et al. 2007). These
mechanisms limit excessive or aberrant cellular proliferation and thus, are thought to
protect cells against the development of cancer. Cellular senescence also has beneficial
effects in embryonic development and wound healing, but the persistence and
accumulation of senescent cells, usually with age, in various tissues can also impair
function and contribute to both aging and pathogenesis of many age-related diseases
(McCulloch, Litherland et al. 2017), like glaucoma, cataracts, the diabetes and
osteoarthritis (Childs, Durik et al. 2015). Furthermore, senescent cells produce
proinflammatory and matrix-degrading molecules in what is known as the senescence-
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associated secretory phenotype (SASP), which may play a causal role in diseases like
atherosclerosis, diabetic fat, cancer, and pulmonary fibrosis (Childs, Durik et al. 2015).
Markers of senescent cells include high expression of cell cycle regulators (p16 and p21),
SASP factors like interleukin-6 (IL6), and an increase in senescence-associated βgalactosidase (SA-β-gal) activity, among others (Kirkland, Tchkonia et al. 2017). Recent
evidence also suggests that accumulation of senescent cells can disrupt normal tissue
functioning. Through SASP, senescent cells could release a large number of proinflammatory cytokines, chemokines, growth factors, and proteases. Through these
components, senescent cells establish a secretory phenotype that could give rise to a
systemic inflammatory situation, and is related to aging (Osorio, Barcena et al. 2012).
Many chemotherapeutic drugs change cellular states, including the induction of
senescence, in cancer cells and tumor microenvironment (Demaria, O'Leary et al. 2017).
For example, DOX induces cellular senescence in human ovarian cells both in vivo and
in vitro (Soleimani, Heytens et al. 2011), and cytotoxic chemotherapy potently induces
the expression of cellular senescence markers, like p16INK4a(p16) in peripheral blood T
cells (Sanoff, Deal et al. 2014). However, how chemotherapy influences cellular
senescence and whether chemotherapy-induced cellular senescence is related to the late
effects of chemotherapy remain to be determined. This knowledge gap is significant
enough to hamper the progress in both basic science and translational medicine
development.
Thus far, researchers have been using cell lines (Soleimani, Heytens et al. 2011)
and human tissue samples (Sanoff, Deal et al. 2014) to investigate the relationship
between chemotherapy and senescence/aging. However, aging is a systemic process,

4

involving almost all the cells, tissues, and organs across the body. Researches with
human tissue samples (Sanoff, Deal et al. 2014) is restricted since we can only check the
senescence markers in human tissue samples and cannot manipulate them to investigate
the senescence mechanism. At the same time, researches with cell lines (Soleimani,
Heytens et al. 2011) are unable to examine the systemic, whole-body response to
chemotherapy.
1.4 CYCLOOXYGENASE
Cyclooxygenase (COX) is a rate-limiting enzyme for the conversion of
arachidonic acid to prostanoids, which exert their effects by activating rhodopsin-like
seven transmembrane spanning G protein-coupled receptors (GPCRs), which, upon
binding with prostanoids, activate the intracellular signaling (Ricciotti and FitzGerald
2011). In the COX signaling cascade, when stimuli appear, the 20-carbon fatty acid
arachidonic acid is freed from membrane phospholipids by phospholipase A2 (PLA2)
and then converted to an unstable intermediate prostaglandin H2 (PGH2) by COX.
Unstable PGH2 is quickly converted to one of five prostanoids (PGD2, PGE2, PGF2α,
PGI2 and TXA2) by tissue-specific prostanoid synthases. Prostanoids exert their effect by
activating a group of GPCRs. Two GPCRs, DP1 and DP2, are activated by PGD2, four
GPCRs by PGE2 (EP1, EP2, EP3, EP4), while IP, FP and TP are activated by PGI2,
PGF2α, and TXA2, respectively (Jiang and Dingledine 2013).
COX exists as two related but unique isoforms: COX1 and COX2. While
constitutive expression of COX1 is believed to play a role in tissue homeostasis, COX2
expression is highly induced by various environmental stresses such as drugs, UV,
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cigarette smoke, diet, and infection (Shim, Foley et al. 2010). Therefore, increased
expression of COX2 is an indicator of both cellular and environmental stresses.
Studies have implicated that COX2 is involved in the development and/or
progression of age-related diseases including atherosclerosis (Cipollone 2005), arthritis
(Woods, Mogollon et al. 2003), cancer (Sobolewski, Cerella et al. 2010), osteoporosis
(Raisz 2005), and Alzheimer's disease (O'Banion 1999). In addition, COX2 expression is
increased in tissues of aged humans and mice. In aged rodents, increased COX2
expression has been reported in the heart, prostate, liver, kidney, and macrophages
(Hayek, Mura et al. 1997, Kim, Baek et al. 2001, Badawi, Liu et al. 2004, Choi, Kim et
al. 2014, Tung, Rodriguez-Bies et al. 2015). The increased COX2 expression has also
been reported in the senescent tissues of aged humans, including skin, mononuclear cells,
and kidney (Melk, Schmidt et al. 2004, Kang, Van Der Zypp et al. 2006, Habib, Salem et
al. 2014, Surowiak, Gansukh et al. 2014). The National Institute of Aging (NIA)
Interventions Testing Program has tested agents to evaluate their effect on the lifespan of
genetically heterogeneous mice. Such efforts have identified that aspirin, a classical nonsteroidal anti-inflammatory drug (NSAID), which is a COX inhibitor, increases lifespan
(Phillips and Leeuwenburgh 2004). Recent studies also reported the pro-longevity effect
of ibuprofen (He, Tsuchiyama et al. 2014) and celecoxib (Ching, Chiang et al. 2011),
both of which are also COX inhibitors. Caloric restriction, which is the only method
known so far to suppress aging, decreases COX2 expression and activity (Jung, Lee et al.
2009). COX2 is also well known for its role in inflammation, but recent studies have
shown that this enzyme also has anti-inflammatory activity (Luo, Urgard et al. 2011), and
COX2 can also be induced by chemotherapy treatment (Altorki, Port et al. 2005).
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Although many studies focused on the role of chemotherapy-induced COX2 in cancer
cells, the role of chemotherapy-induced COX2 in normal cells remains to be determined.
1.5 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
As the most frequently consumed drugs worldwide (Frolich 1997), NSAIDs are a
chemically heterogenous group of agents that are widely used for their anti-inflammatory,
antipyretic, and analgesic properties (Pirlamarla and Bond 2016). There are important
differences amongst the various NSAIDs, which are not explained by differences in
pharmacokinetics and are often of therapeutic relevance. The discovery of two different
COXs, now known as COX1 and COX2, provides an explanation for these and other
differences (Frolich 1997). NSAIDs act by inhibiting COX1 and/or COX2 (Day and
Graham 2013), and NSAIDs are classified depending on which COX isoenzyme they
preferentially block. Traditionally, the selective COX2 inhibitors include SC-236
(Masferrer, Koki et al. 1999), celecoxib (Goldstein, Silverstein et al. 2000), rofecoxib,
valdecoxib, parecoxib, etorioxib, and lumaricoxib (Pirlamarla and Bond 2016). Few sole
COX1 inhibitors have also been identified, like resveratrol (Brzozowski, Konturek et al.
2001). NSAIDs that inhibit both COX1 and COX2 are known as the nonselective
NSAIDs, and include aspirin (Brzozowski, Konturek et al. 2001), sulindac (Oshima,
Dinchuk et al. 1996), diclofenac, naproxen, ibuprofen, indomethacin, and piroxicam
(Pirlamarla and Bond 2016).
Aspirin is one of the oldest and most widely used NSAIDs, exerting its function
through inhibiting both COX1 and COX2 (Brzozowski, Konturek et al. 2001, Vane and
Botting 2003). Its related usage has been documented from 2400 years ago by
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Hippocrates (Grammaticos and Diamantis 2008). Already approved by FDA, aspirin has
widely used in numerous conditions like cardiovascular disease, pain, and inflammation
(Fuster and Sweeny 2011). Studies have even shown that a regular dose of aspirin can
prolong life since aspirin reduces the risk of many diseases associated with aging (Vane
and Botting 2003). However, the mechanism of aspirin in preventing aging is still not
known yet.
1.6 SENOLYTIC DRUGS
The numbers of senescent cells increase with aging in mice, monkeys, and
humans, and intervention that increase lifespan, like caloric restriction is associated with
decreased senescent cell abundance (Kirkland, Tchkonia et al. 2017). Drug AP20187
does not affect wild-type mice, but it activates a suicide protein encoded by a transgene,
which is present in only p16-expressing cells in INK-ATTAC transgenic mice. Using this
INK-ATTAC mice line, from which senescent cells can be eliminated using drug
AP20187, special removal of p16-positive senescent cells can prevent or delay tissue
dysfunction and extend healthspan (Baker, Wijshake et al. 2011).
To remove senescent cells pharmacologically from non-genetically modified
mice, senolytic drugs, are being developed. Two recent studies (Demaria, O'Leary et al.
2016, Baar, Brandt et al. 2017) have shown that selective removal of chemotherapyinduced senescent cells ameliorates adverse effects of chemotherapy and improves tissue
homeostasis. Recently, several senolytic drugs have been reported with the ability of
eliminating senescent cells, including quercetin, dasatinib (Zhu, Tchkonia et al. 2016),
ABT263 (Chang, Wang et al. 2016), ABT737 (Yosef, Pilpel et al. 2016), FOXO4-DRI
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(Baar, Brandt et al. 2017). However, each has critical disadvantage: Quercetin,
ABT263/737 and FOXO4-DRI are not FDA-approved, and while quercetin, dasatinib,
ABT263/737 are non-specific (Zhu, Tchkonia et al. 2016, Baar, Brandt et al. 2017).
Therefore, we need a drug which specifically targets senescent cells and FDA-approved,
to quickly facilitate its therapeutic use.
1.7 P53
p53 is a tetrameric transcription factor and is a well-known tumor suppressor. It
induces growth arrest or apoptosis program in response to a plethora of different cellular
stresses (Brady and Attardi 2010). In normal cells, p53 is a short-lived protein which is
continuously undergoing ubiquitination and subject to proteasomal degradation. MDM2,
one of the first characterized p53 targets, serves as a major E3 ubiquitin ligase for p53
degradation and thus forms a negative autoregulatory loop to maintain the low level of
p53 expression in unstressed conditions (Qian and Chen 2013). Upon genotoxic stresses,
rapid phosphorylation of p53 at Ser15 by Ataxia telangiectasia mutated (ATM), a
serine/threonine protein kinase, and at Ser20 by checkpoint kinase 2 (Chk2) causes
dissociation of p53 from MDM2, resulting in p53 stabilization and activation of its
downstream processes (Qian and Chen 2013). Many DNA damage-inducing drugs target
tumors through p53-mediated apoptosis (Rufini, Tucci et al. 2013), and in addition, they
also induce cellular senescence (Qian and Chen 2013). The main role of p53 is to
eliminate damaged cells, either by triggering apoptosis or senescence. However,
uncontrolled activity of p53 results in the excessive elimination of cells that exhausts the
capacity of tissue regeneration, leading to premature aging (Collado, Blasco et al. 2007).
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CHAPTER 2
FUNCTIONAL SIGNIFICANCE OF INCREASED COX2 EXPRESSION
DURING AGING
2.1 GENERATION OF INDUCIBLE COX2 TRANSGENIC MICE
To investigate the role of COX2 in cellular senescence and aging, we have
generated the COX2 transgenic mouse model using Cre-loxP system. A diagram of the
COX2 transgene is shown in Figure 2.1. In this construct, the cytomegalovirus early
enhancer/chicken β-actin (CAG) promoter directs the expression of the human COX2
gene. COX2 expression is blocked by a chloramphenicol acetyl transferase (CAT)
reporter gene flanked by two loxP sites. Two independent lines of floxed CAT/COX2
mouse (CATflCOX2) were produced. Since embryonic expression of COX2 causes
various malformations and postnatal lethality (Shim, Foley et al. 2010), an inducible
COX2 transgenic mouse model was generated. CATflCOX2 mice were crossed with
ROSA-Cre ERT2 mice carrying a Cre recombinase-estrogen receptor-T2 allele targeted
to the ubiquitously expressed ROSA26 locus (Ventura, Kirsch et al. 2007). Tamoxifeninducible, Cre-mediated recombination at loxP sites results in deletion of the interfering
CAT gene. In this way, human COX2 could be expressed under the control of the CAG
promoter in the COX2 transgenic mouse, which has both floxed COX2 and Cre-ERT2
alleles. COX2 transgenic mice without tamoxifen treatment appeared to be normal. To
study the effect of COX2 in mouse, 5~6-week-old COX2 transgenic and control
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littermates were intraperitoneally injected with tamoxifen, and mosaic expression of
COX2 was observed in the tissues of 20-week-old COX2 transgenic mice, including the
heart, skin, muscle, pancreas, small intestine, and kidney (Figure 2.2).
2.2 AGING PHENOTYPES IN COX2 TRANSGENIC MICE
Tamoxifen-injected COX2 transgenic mice appeared normal until the age of 20
weeks, when we first noticed an unkempt and greasy hair coat (Figure 2.3). Reduced
subcutaneous fat is one of the markers for aged skin (Tyner, Venkatachalam et al. 2002).
The analysis of hematoxylin and eosin (H&E)-stained sections of skin revealed a
reduction in the subcutaneous fat in 20-week-old COX2 transgenic mice when compared
to the skin in tamoxifen-injected control littermates (Figure 5 A-D, n=12). Additionally,
hyperplasia of the sebaceous gland (Figure 2.4 E-F) was observed in COX2 transgenic
skin, as is also observed in aged human skin (Kumar, Barton et al. 1988, Zouboulis and
Boschnakow 2001), and in the skin of XPD mutant mice, which exhibit premature aging
phenotypes (de Boer, Andressoo et al. 2002).
Hair regrowth also declines as a function of age in mice (Harrison and Archer
1988), and is reduced in other mouse models of aging (Tyner, Venkatachalam et al. 2002,
Li, Zhao et al. 2013). Thus, a hair re-growth assay was performed to investigate the
impact of COX2 on hair growth. In mouse skin, coordinated hair regeneration occurs in a
wave-like pattern across the skin surface. However, in old mice, waves of hair growth
slow down, or hair cycle domains fragment into smaller domains, resulting in patchy hair
growth (Chen, Murray et al. 2014). As shown in Figure 2.5, delayed or patchy re-growth
of hair was observed in all COX2 transgenic mice, whereas the age-matched control mice
exhibited normal hair re-growth 20-days after removal of hairs.
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Tamoxifen-induced COX2 transgenic mice exhibited other signs of aging. The
lifespan of COX2 transgenic mice was significantly reduced compared to that of control
mice (Figure 2.6 A). Studies have shown that there is a reduction in muscle fiber size
with increasing age (Welle 2002). As shown in Figure 2.6 B and C, the size of the muscle
fiber in the hind leg of COX2 transgenic mice was reduced compared to that in control
littermates (n=5). The increase in heart weight is normally found in the aging human
heart (Waller 1988, Melissari, Balbi et al. 1991). The heart weight relative to body weight
was increased in COX2 transgenic mice (Figure 2.6 D, n=9) compared to that in control
littermates. We also performed quantitative assessments of body composition with X-ray
densitometry of the whole mouse. The fat content was reduced in COX2 transgenic mice
compared to control littermates, consistent with the results from histological analysis of
subcutaneous fat (Figure 2.6 E, n=5). COX2 transgenic mice also exhibited changes in
peripheral blood composition. White blood cell counts in transgenic animals were
significantly lower than those in control littermates (Figure 2.6 F). In addition, some
COX2 transgenic mice developed ocular abnormalities such as opaque eyes and
blindness (Figure 2.6 G).
Female fertility decreases with age, and males develop an age-associated decline
in sperm count (Pal and Santoro 2003). We set up matings between 10 COX2 transgenic
males (12 ~ 23 weeks old) and 10 wild-type females. However, none of the wild-type
females became pregnant after two months of being housed together. Testes of the COX2
transgenic males were generally smaller than wild-type testes (Figure 2.7 A). Histological
analysis of transgenic testes revealed the absence or reduced number of mature
spermatozoa (Figure 2.7 B). We also set up matings between 12 COX2 transgenic
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females and 12 wild-type males. However, only one out of the 12 transgenic females
became pregnant. Histological analysis showed that the ovaries of 40-week-old COX2
transgenic mice were atrophic with minimal follicles and compensatory interstitial
hyperplasia, which suggests that these ovaries have been exhausted (Figure 2.8 A-C).
Additionally, ovarian bursal cysts were often observed in COX2 transgenic female mice
(Figure 9 D and E), which is commonly observed in aged mice (Dixon, Alison et al.
2014).
The incidence and severity of pancreatitis increases in elderly population
(Browder, Patterson et al. 1993, Fagenholz, Castillo et al. 2007, Frey, Zhou et al. 2007).
Colby et al. have shown that bovine keratin 5 promoter-driven expression of COX2 in
dysplastic changes in the pancreas (Colby, Klein et al. 2008). Consistent with their
findings, pancreata of COX2 transgenic mice exhibited phenotypes similar to chronic
pancreatitis such as the loss of the pancreatic acini, the increase of the metaplastic
pancreatic ducts with dysplastic changes, periductal fibrosis, and mononuclear
inflammatory cell infiltration in the highly vascularized fibrotic stroma (Figure 2.9).
Hyperplasia of the Langerhans islets was also noticed, which is often associated with age
in mice (Brunnert, Herron et al. 1990).
2.3 INCREASED SENESCENCE IN COX2 TRANSGENIC MICE
Cellular senescence has been proposed to contribute to aging phenotypes and/or
the development of certain age-related diseases (Campisi 2003). The number of senescent
cells increases with age in mammalian tissues (Campisi 2005), and such cells have been
found at sites of age-related pathologies such as osteoarthritis and atherosclerosis (Price,
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Waters et al. 2002, Matthews, Gorenne et al. 2006). Immunohistochemical analysis of
p16, an indicator of senescence, revealed that the number of p16-positive cells was
increased in the pancreata of COX2 transgenic mice compared to that in pancreata of
control littermates (Figure 2.10 A and B). In addition, immunohistochemical analysis of
phospho-H2AX, a marker of DNA damage, showed that the number of phospho-H2AXpositive cells was increased in the pancreata of transgenic mice (Figure 2.10 C and D).
Similarly, Western blot analysis showed increased levels of p16 and phospho-H2AX in
transgenic pancreas (Figure 2.11). Increase in the number of phospho-H2AXpositive cells
was also observed in the skin of COX2 transgenic mice (Figure 2.10 E and F).
To determine whether increased COX2 expression is associated with the
increased cellular senescence, we performed senescence-associated beta-galactosidase
(SA-β-gal) staining (Debacq-Chainiaux, Erusalimsky et al. 2009) using adult mouse lung
fibroblasts isolated from control and COX2 transgenic mice. The isolated fibroblasts
were incubated with 1μM of 4-hydroxytamoxifen to induce COX2 expression. As shown
in Figure 2.12 A-C, the number of SA-β-gal-positive cells was increased in COX2
transgenic fibroblasts compared to that in control fibroblasts. However, treatment of
COX2 transgenic fibroblasts with NS-398, a COX2 specific inhibitor, significantly
reduced the number of SA-β-gal-positive cells (Figure 13 A and B). These results suggest
that premature aging phenotypes may be linked to COX2-mediated induction of cellular
senescence.
In summary, post-natal expression of COX2 led to a panel of aging-related
phenotypes, and additionally, adult mouse lung fibroblasts from COX2 transgenic mice
exhibited increased SA-β-gal activity. These results suggest that the increased COX2
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expression has an impact on the aging process and that modulation of COX2 and its
downstream signaling may be an approach for the intervention of age-related disorders.
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Figure 2.1 Generation of COX2 transgenic mouse. Diagram of CAG/CAT/hCOX2
construct is shown.
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Figure 2.2 Expression of COX2 in various tissues of tamoxifen-inducible COX2
transgenic mouse. COX2 expression was induced in 5-week-old (CATflCOX2:RosaCre ERT2) mice by intra-peritoneal injections of tamoxifen. Paraffin-embedded
sections of 20-week-old COX2 transgenic mice were stained for COX2 using a human
COX2-specific antibody. The tissues shown are heart (A), kidney (B), skeletal muscle
(C), pancreas (D), small intestine (E), and skin (F). Scale bar=100µm
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Figure 2.3 Appearance of control and transgenic mice. Representative photographs of
general appearance of 20-week-old control (CT) and COX2 transgenic (TG) mice.
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Figure 2.4 COX2 transgenic expression decreased subcutaneous fat. Cross-sections of
dorsal skin from 20 weeks-old control (A, C and E) and COX2 transgenic (B, D, and
F) littermate. Epidermis (E), dermis (D), adipose under the dermis (A), and muscle
(M) are indicated. The COX2 transgenic skin exhibits sebaceous gland hyperplasia
and a decrease in subcutaneous fat and muscle. (G) Quantification of the thickness of
subcutaneous fat in control and COX2 transgenic mice (***: p<0.001).
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Figure 2.5 COX2 transgenic expression slowed hair growth rate. A representative
photo of 20 weeks-old COX2 transgenic and age-matched control male mice at 20d
after hair removal on a dorsal area, and quantification of hair re-growth in control and
COX2 transgenic mice (***: p<0.001)
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Figure 2.6 COX2 transgenic expression resulted in various aging phenotypes. (A)
Longevity in control (n=23) and COX2 transgenic (n=25) mice. (B) H&E stained
sections of hind leg skeletal muscle from 22-week-old control (CT) and COX2
transgenic (TG) female littermates. Cross sections of the extensor digitorum longus
(EDL) muscle are shown. Scale bar=100µm. (C) Frequency distribution of skeletal
muscle fiber cross-sectional area (CSA) between control (CT) and COX2 transgenic
(TG) mice. (D) Heart weight/body weight (HW/BW) ratios in tamoxifen-induced
control (CT) and COX2 transgenic (TG) male littermates at the age of 22 weeks.
HW/BW ratios in COX2 transgenic mice were significantly higher than those in
control mice (paired t-test, p<0.001). (E) Quantitative assessment of fat content by Xray densitometry of control (CT) and transgenic (TG) mice (n=5). (F) White blood
cell (WBC) counts in tamoxifen-induced control (CT) and COX2 transgenic
littermates (paired t-test, *: p<0.05, **: p<0.01, n=4). (G) The opacity of cornea
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Figure 2.7 Male fertility decreased after COX2 transgenic expression. (A) Testis from
25 weeks-old control (CT) and COX2 transgenic (TG) male littermate at the age of 25
weeks. The size of the testis is reduced in COX2 transgenic mice (n=3). (B) Crosssections of testis of control (CT) and COX2 transgenic (TG) mice at 22 weeks. While
control testis the contains the sperm (arrows), the sperms were not observed in COX2
transgenic testis.
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Figure 2.8 Female fertility decreased after COX2 transgenic expression. H&E staining
of ovarian sections from 40-week-old (A) control (CT) and (B) COX2 transgenic mice
(magnification x5). (C) Higher magnification (x10) view of the ovary shown in (B).
(D) The ovary from 22-week-old COX2 transgenic mouse showing a cystic structure
filled with a clear fluid (arrow). (E) H&E stained bursal cyst in COX2 transgenic
mouse. The cyst contains pale eosinophilic proteinaceous material. Scale bar=100μm.
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Figure 2.9 H&E stained sections of pancreas from COX2 transgenic mice (TG)
showing the loss of the pancreatic acini, the increase of the metaplastic pancreatic
ducts with dysplastic changes, peri‐ductal fibrosis, and mononuclear inflammatory
cell infiltration in the highly vascularized fibrotic stroma. Hyperplasia of the
Langerhans islets was also noticed. Scale bar=100μm.

24

Figure 2.10 (A) and (B) Immunohistochemical staining of p16 in the pancreata from
25-week-old control and COX2 transgenic littermates (magnification x20). (C) and
(D) Immunohistochemical staining of phosphor-H2AX in the pancreata from 23week-old control and COX2 transgenic littermates (magnification x20). (E) and (F)
Immunohistochemical staining of phosphor-H2AX in the skin from 25-week-old
control and COX2 transgenic littermates (magnification x20). Scale bar=100µm.
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Figure 2.11 Western blot analysis of COX2, phosphor-H2AX, and p16 in pancreas of
control (CT) and COX2 transgenic (TG) mice.
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Figure 2.12 COX2 transgenic expression increased cellular senescence level. (A) and
(B) Adult mouse lung fibroblasts from control and COX2 transgenic mice were
incubated with 4-hydroxytamoxifen for 24 hours to induce COX2 expression in
transgenic fibroblasts. The cells were cultured in the regular culture medium for 48
hours before SA-β-Gal staining. Representative pictures from 3 independent
experiments are shown. Quantification results are shown in (C).
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Figure 2.13 (A) Adult mouse lung fibroblasts from control and COX2 transgenic mice
were incubated with 4-hydroxytamoxifen for 24 hours to induce COX2 expression in
transgenic fibroblasts. The cells were cultured in the regular culture media containing
DMSO or 10µM NS398 for 72 hours before SA-β-gal staining. Quantification results
are shown in (B).
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CHAPTER 3
DEVELOPMENT OF A MOUSE MODEL OF CHEMOTHERAPYINDUCED AGING
3.1 ANALYSIS OF AGING PHENOTYPES IN DOX-TREATED MICE
DOX is frequently used in the treatment of childhood cancer. We used DOX as a
chemotherapeutic agent in our studies because DOX has been shown to induce
senescence in both humans and mice (Sanoff, Deal et al. 2014, Demaria, O'Leary et al.
2016, Baar, Brandt et al. 2017), and because anthracyclines including DOX have been
widely used to treat children with cancer in the past, suggesting that many current
survivors of childhood cancer may have received DOX treatment. Mouse models have
been used to study DOX-induced chronic or acute cardiotoxicity (Delgado, Nawar et al.
2004, Neilan, Blake et al. 2007, Yalcin, Oruc et al. 2010, Kim, Kim et al. 2015).
However, these models used adult mice (6~12 weeks old), and DOX-treated mice often
die due to complications in cardiac function. To investigate the late effects of
chemotherapy, we developed a new mouse model in current study.
Protocols for DOX treatment for both adults and children use a maximum
cumulative dose of 450-550 mg/m2 (Harake, Franco et al. 2012), equal to 18-22 mg/kg.
Childhood malignancy patients could get mean cumulative DOX dose of 406mg/m2
(Lipshultz, Lipsitz et al. 2002), equal to 16.24mg/kg. Several chemotherapy studies in
rats used a cumulative dose of 15mg/kg body weight of DOX given over six equal
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injections (Harake, Franco et al. 2012). We chose a relatively low DOX dose intensity,
10mg/kg cumulative dose, and treated C57BL/6 mouse according to Figure 3.1. DOXtreated mice exhibited reduced body weight (Figure 3.2 A and B), compared to PBSinjected littermates. In addition, DOX-treated mice showed decreased inguinal fat weight
(Figure 3.3 A and B) and epididymal fat weight (Figure 3.3 C and D). Additionally,
various essential organs also exhibited reduced weight, like liver (Figure 3.4 A and B),
spleen (Figure 3.4 C and D), pancreas (Figure 3.5 E and F), and lung (Figure G and H),
indicating general decline in body function after DOX treatment. Some DOX-treated
mice also exhibited pronounced lordokyphosis (Figure 3.2 C), another sign of aging.
To analyze the effect of DOX on reproduction capacity, 4 DOX-treated male mice
were kept in the same cage with 4 female control mice of the same age, and none of these
female mice were found pregnant. Additionally, when 4 female DOX-treated mice were
set in the same cage with 4 male control mice of the same age, only 1 out of these 4
females were found pregnant, indicating that DOX treatment causes a decline in
reproductive capacity. Together, these observations suggest that treatment of juvenile
mice with DOX may cause early aging.
3.2 HISTOLOGICAL ANALYSIS OF TISSUE AGING
To further analyze the effect of DOX on tissue aging in vivo, various tissue
samples from both control and DOX-treated mice were fixed with 10% formaldehyde.
Samples were then embedded into paraffin blocks and sectioned into 5µm sections.
Sections were stained with hematoxylin and eosin for histological analysis.
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Hematoxylin and eosin (H&E) staining of skin sections showed decreased
subcutaneous fat (Figure 3.5), and muscle fiber size (Figure 3.6) in DOX-treated mice,
compared to control littermates. DOX-treated mice also had decreased testicle weight
(Figure 3.7), and reduced sperm population in the testicle (Figure 3.8), confirming the
reduced reproductive capacity under DOX influence.
3.3 ANALYSIS OF CELLULAR SENESCENCE AFTER DOX TREATMENT
Accumulation of senescent cells is associated with aging (Campisi 2013), and
DOX is known to induce cellular senescence (Soleimani, Heytens et al. 2011). As shown
in Figure 3.9, treatment of WI38, a normal human fibroblast cell line, with DOX,
increased the number of SA-β-gal positive cells (increased by more than 6 folds from
9.7% to 59.4%), confirming that this chemotherapeutic agent induces cellular senescence.
DOX-treated mice, along with control littermates, were sacrificed and various
tissues were harvested and embedded in Embedding Medium for Frozen Tissue
Specimens to ensure Optimal Cutting Temperature (O.C.T) Compound. Cryosections
were made from these samples, and SA-β-gal staining assay was performed to check the
cellular senescence level in vivo. Increased number of SA-β-gal positive cells was
observed in liver (Figure 3.10 A), spleen (Figure 3.10 B), pancreas (Figure 3.10 C), and
lung (Figure 3.10 D) in DOX-treated mice, comparing to their control littermate,
indicating that DOX causes cellular senescence not only in vitro (Figure 3.9), but also in
vivo.
In the liver of DOX-treated mice, the senescent cells accumulated in liver
parenchyma (Figure 3.10 A), which is made up of hepatocytes that filter blood to remove
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toxins. The liver is a vital organ of detoxification, and increased cellular senescence level
in liver parenchyma suggests that DOX might damage the detoxification function of the
liver, which could reduce the mouse resistance to DOX toxicity, assisting in the
occurrence of cellular senescence in other organs across the body. The SA-β-gal positive
senescent cells were accumulated in exocrine pancreas (Figure 3.10 C) and in cells
forming alveoli and bronchus in the lung (Figure 3.10 D), indicating that DOX treatment
might impair digestive and respiratory systems.
DOX may also damage the immune system. There are two main compartments in
the spleen, the white pulp and the red pulp. The white pulp contains lymphocytes and
initiates immune responses to blood-borne antigens, while the red pulp is a blood filter
that removes foreign material and damaged and effete erythrocytes, and is also a storage
place for iron, erythrocytes, and platelets. In rodents, it also serves as the site of
hematopoiesis (Cesta 2006). It has been reported that red pulp is also a reservoir of
monocytes, which upon moving into injured tissues, turn into dendritic cells and
macrophages to participate in immune response like inflammation regulation and wound
healing (Swirski, Nahrendorf et al. 2009). In our study, SA-β-gal staining was mostly
observed in red pulp (Figure 3.10 B), suggesting that DOX might impair the mouse
immune response to tissue damage, so that senescent cells can accumulate and stay
longer, and in this way, contributes to the development of early aging phenotypes.
Markers of senescent cells include high expression of cell cycle regulator (p16
and p21), SASP factors like interleukin-6 (IL6), and an increase in cellular senescentassociated β-galactosidase (SA-β-gal) activity, among others (Kirkland, Tchkonia et al.
2017). None of these markers are fully sensitive or specific, so testing more than one
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marker is needed to draw conclusions about the senescence induction effect of DOX.
Based on this, we also tested the mRNA level of multiple cellular senescence markers in
various mouse tissues. The p16 mRNA level was elevated in liver (3.11 A), spleen (3.11
B), and lung (3.11 C), while p21 mRNA level was increased in spleen (3.11 D), liver
(3.11 E), and lung (3.11 F). Besides, we also detected significant increase of IL6 mRNA
level in liver (3.12 A), tibialis anterior (3.12 B), gastrocnemius (3.12 C), spleen (3.12 D),
inguinal fat (3.12 E) and skin (3.12 F), confirming that DOX treatment could induce
general cellular senescence response across the entire body.
In summary, we have established a novel chemically-induced mouse model to
study the cellular senescence, early aging, and late effect of chemotherapy. With this
model, we demonstrated that DOX, a chemotherapeutic agent, induces cellular
senescence and aging phenotypes.
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Figure 3.1 Mouse DOX treatment procedure. Pharmacological treatment procedure of
C57BL/6 with DOX. 2.5 mg/kg DOX was injected into C57BL/6 mouse when the
mouse was 2, 3, 4, and 5-week-old. Various tissues were harvested when the mouse
was 16-18-week-old.
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Figure 3.2 DOX treatment decreased mouse body weight. (A) A representative
photograph of mice after PBS and DX treatment. (B) Body weight curves of PBS and
DX-treated male mice (n=6). (C) A representative photograph of skinned DX-treated
mouse that exhibits pronounced lordokyphosis, along with its littermate control.
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Figure 3.3 DOX treatment decreased inguinal fat weight/body weight ratio and
epididymal fat weight/body weight ratio in mice. (A) A representative photograph of
mouse inguinal fats (Arrows) after PBS (Control) and DOX treatment. (B) Inguinal fat
weight/body weight ratio decreased after DOX treatment (n=5). (C) A representative
photograph of mouse epididymal fats (Arrows) after PBS (Control) and DOX
treatment. (D) Epididymal fat weight/body weight ratio decreased after DOX
treatment (n=5).
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Figure 3.4 DOX treatment decreased organs weight/body weight ratio in mice. (A)
Liver weight/body weight ratio decreased after DOX treatment (n=5). (B) A
representative photograph of mouse livers after PBS (Control) and DOX treatment.
(C) Spleen weight/body weight ratio decreased after DOX treatment (n=5). (D) A
representative photograph of mouse spleens after PBS(Control) and DOX treatment.
(E) Pancreas weight/body weight ratio decreased after DOX treatment (n=5). (F) A
representative photograph of mouse pancreases after PBS (Control) and DOX
treatment. (G) Lung weight/body weight ratio decreased after DOX treatment (n=5).
(H) A representative photograph of mouse lungs after PBS (Control) and DOX
treatment.
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Figure 3.5 DOX treatment decreased subcutaneous fat in mice. (A) Representative
photographs of skin H&E-stained sections after PBS (Control) and DOX treatment.
(B) Subcutaneous fat decreased after DOX treatment (n=7). The skin sample was
embedded into paraffin block and sectioned into 5µm sections. Sections were stained
with hematoxylin and eosin after 1h baking at 60°C within hybridization oven.
Subcutaneous fat width was measured with ImageJ.
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Figure 3.6 DOX treatment decreased muscle fiber size. (A) H&E stained sections of
hind leg skeletal muscle from control and DX-treated male littermate. Cross sections
of the extensor digitorium longus (EDL) muscle are shown. (B) Frequency
distribution of skeletal muscle fiber cross-sectional area (CSA) between control and
DOX-treated mice.

39

Figure 3.7 DOX treatment decreased testicle weight/body weight ratio in mice. (A)
Representative photograph of testicles after PBS and DOX treatment; (B) Testicle
weight/body weight ratio decreased after DOX treatment (n=4).
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Figure 3.8 DOX treatment decreased sperm population in mice. Representative
photographs of testicle H&E-stained sections after PBS (Control) and DOX treatment.
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Figure 3.9 DOX increases the percentage of senescent WI38 cells. WI38 cells were
treated with either DMSO (Control) or 1mM DOX for 2h, and then SA-β-gal staining
assay was performed to check cellular senescence. (A) Representative photographs of
WI38 cells after vehicle (Control) and DOX treatment. (B) SA-β-gal-positive cell
number increased after DOX treatment.
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Figure 3.10 DOX induced cellular senescence in vivo. DOX caused cellular
senescence in liver (A), spleen (B), pancreas (C), and lung (D) in vivo. R: Red pulp;
W: White pulp.
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Figure 3.11 DOX caused cellular senescence markers, p16 and p21, in mouse tissues.
p16 mRNA level was increased after DOX treatment in liver (A), spleen (B) and lung
(C). p21 mRNA level was increased after DOX treatment in spleen (D), liver (E), and
lung (F).
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Figure 3.12 DOX caused cellular senescence markers, IL6, in mouse tissues. of liver
(A), tibialis anterior (B), gastrocnemius (C), spleen (D), inguinal fat (E), and skin (F).

45

CHAPTER 4
ROLE OF COX2 IN CHEMOTHERAPY-INDUCED CELLULAR
SENESCENCE AND AGING
4.1 ANALYSIS OF COX2 EXPRESSION IN TISSUES OF DOX-TREATED MICE
It has been reported that chemotherapeutic agents induce COX2 expression
(Altorki, Port et al. 2005, Brown and DuBois 2005, Hwang, Ha et al. 2005, Logan,
Gibson et al. 2007). Since inducible COX2 expression in adult mice accelerated aging
phenotypes, we hypothesized that COX2 contributes to the aging phenotypes in DOXtreated mice. To test this hypothesis, protein lysates were made from the tissues of the
mice treated with either PBS or DOX, and western blotting was performed to check the
COX2 protein level. Increased COX2 expression was observed in skin, liver, inguinal fat,
and thymus of DOX-treated mice (Figure 4.1), suggesting that DOX-induced cellular
senescence and aging phenotypes may be mediated by COX2.
4.2 IN VITRO ANALYSIS OF THE EFFECT OF COX2 DELETION ON
CHEMOTHERAPY-INDUCED SENESCENCE
As previously mentioned, chemotherapy is known to induce COX2 expression.
To analyze the role of COX2 in DOX-induced cellular senescence, MEFs were isolated
from COX2 knockout and WT embryos (Figure 4.2). Wild type and COX2 KO MEFs
were then treated by 0.2µM DOX for 24h to induce cellular senescence. As shown in
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Figure 4.3, SA-β-gal staining showed that the number of senescent cells was significantly
reduced in COX2 KO MEFs comparing to that in WT MEFs, suggesting that COX2 is
involved in DOX-induced cellular senescence.
4.3 IN VIVO ANALYSIS OF P53 AND P21 IN DOX-TREATED MICE
Increased p53 expression was observed in COX2 transgenic mouse embryos
(Shim, Foley et al. 2010). In addition, we recently have demonstrated that COX2
regulates DNA damage-induced expression of p53 through modulation of oxidative stress
(Kim and Shim 2016). Additionally, p53 is known to play an important role in cellular
senescence and aging (Collado, Blasco et al. 2007), and targeting p53 signaling has been
reported as a feasible strategy to induce apoptosis of senescent cells (Baar, Brandt et al.
2017). Therefore, we hypothesized that DOX mediates cellular senescence and aging
phenotypes through COX2-p53 signaling.
To examine whether p53 expression is altered in COX2 transgenic mice, we
assessed the levels of p53 in the tissues of control and COX2 transgenic mice. Western
blot analysis revealed that expression of p53 was increased in various tissue lysates
(pancreas, skin, and muscle) of COX2 transgenic mice (Figure 4.4).
To determine whether p53 is involved in DOX-induced senescence and aging,
protein lysates were made from the various tissue of mouse treated with either DOX or
PBS (Control), and subjected to Western blot analysis for p53 and p21. p21 is a cyclindependent kinase inhibitor that is capable of inhibiting all cyclin/CDK complexes and is a
downstream target of p53 signaling. As shown in Figure 4.5, both p53 and p21 protein
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levels were increased in the tissues of DOX-treated mice, including liver, skin, spleen,
thymus, testicle, and lung, indicating that DOX-treatment also induces p53 signaling.
In addition, wild type and COX2 KO MEFs, isolated from WT and COX2 KO
embryos, were treated with 0.2µM DOX for 24h to induce cellular senescence. The
protein level of p53 and p21 were analyzed with western blotting. As shown in Figure
4.6, COX2 knockout could decrease DOX-induced p53 and p21 level. This encouraged
us to investigate how COX2 is involved in DOX-induced cellular senescence and aging.
To future determine whether COX2 inhibition affects p53 levels, WI38 cells were
treated with DOX in the presence of either non-selective COX inhibitors (aspirin and
piroxicam), or selective COX2 inhibitors (DuP-697 and celecoxib). As shown in Figure
4.7, the DOX-induced increase in p53 levels was decreased after treatment with either
non-selective or selective COX2 inhibitors. These results suggest that COX2 may
regulate cellular senescence and/or aging through modulation of p53 signaling.
4.4 THE EFFECT OF COX INHIBITOR ON AGING-PHENOTYPES IN DOXTREATED MICE
Non-steroidal anti-inflammatory drugs (NSAIDs) are believed to exert their
effects by inhibiting prostaglandin synthesis through COX inhibition. Among these
NSAIDs, aspirin has been used for more than one hundred years (Hawkey 1999). In
DOX-treated mice, we observed not only aging phenotypes, but also increased COX2
level. This led us to wonder if COX2 plays a critical role in this DOX-induced aging
process, and thus if inhibiting COX2 could recover DOX-induced aging phenotypes. To
test this, DOX- or PBS-treated mice were fed aspirin according to Figure 4.8.
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As expected, DOX-treated mice showed reduced body weight. However, aspirin
treatment recovered body weight in DOX-treated mice (Figure 4.9 A) In addition, the
white blood cell (WBC) loss caused by DOX (Figure 4.9 B), which is also an indicator of
aging (de Labry, Campion et al. 1990), was also recovered by aspirin feeding. These
results suggest that COX may play a role in DOX-induced aging phenotypes.
Besides these, other aging phenotypes observed in DOX-treated mice were also
recovered after aspirin treatment, like decreased inguinal fat weight (Figure 4.10),
decreased epididymal fat weight (Figure 4.11), and decreased sperm population (Figure
4.12). Decreased weight of other tissues, like brown adipose tissue, testicle and lung, was
recovered too (Figure 4.13). Histological analysis of tissue sections revealed recovered
level of subcutaneous fat loss (Figure 4.14), muscle fiber size decrease (Figure 4.15),
inguinal adipocyte size decrease (Figure 4.16) and brain neuron necrosis (Figure 4.17).
Additionally, the DOX-induced inguinal fat inflammation, as shown by necrosis and
immune cell infiltration (Figure 4.16), was also down-regulated with aspirin treatment.
These data indicate that COX inhibition with aspirin could reverse DOX-induced aging
phenotypes.
4.5 THE EFFECT OF ASPIRIN ON DOX-INDUCED CELLULAR SENESCENCE IN
VIVO
The fact that aspirin recovered DOX-caused aging phenotypes encouraged us to
test if aspirin could also recover the in vivo cellular senescence induced by DOX. SA-βgal in vivo staining was performed with cryosections of liver, spleen, pancreas, and lung,
from which we have already proved that DOX induces cellular senescence. Figure 4.18
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shows that aspirin significantly decreased the number of senescent cells in all these four
organs. Indeed, DOX-elevated levels of senescent markers, p16 and IL6, were also
significantly decreased with aspirin treatment in tissues like liver, inguinal fat, and spleen
(Figure 4.19). This result indicates that COX activity may play a role in DOX-induced
cellular senescence.
4.6 COX AS A TARGET TO REVERSE DOX-INDUCED AGING
Aspirin has also been reported with functions independent of COX signaling.
Aspirin diffuses from mitochondria intermembrane space as a proton carrier into the
mitochondrial matrix, from where it ionizes to release protons. In this way, it acts as a
competitor to ATP synthase, uncoupling oxidative phosphorylation in cartilaginous and
hepatic mitochondria to cause hyperthermia due to large amount of released heat from
electron transport chain, as opposed to the expected antipyretic action (Somasundaram,
Sigthorsson et al. 2000). Also, aspirin could promote NO radical formation, resulting in
reduced leukocyte adhesion and further decreased inflammation level (Paul-Clark, Van
Cao et al. 2004). Additionally, it might also act through NF-κB (McCarty and Block
2006), which’s pathway has long been considered a prototypical proinflammatory
signaling pathway based on the role of NF-κB in the expression of proinflammatory
genes including cytokines, chemokines, and adhesion molecules (Lawrence 2009).
To confirm that the aging rescue effect of aspirin comes from its COX inhibition
activity, we tried to use COX2 knockout mouse (COX2 KO) to repeat this experiment.
COX1 and COX2 are key enzymes in prostaglandin biosynthesis (Langenbach, Morham
et al. 1995). While homozygous COX1 mutant mice exhibited decreased inflammatory
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response and reduced fertility (Langenbach, Morham et al. 1995), possibly due to
decreased platelet aggregation, delayed parturition and neonatal death (Gross, Imamura et
al. 1998), absence of COX2 resulted in female infertility because of severe renal
pathology (Morham, Langenbach et al. 1995) and defective decidualization (Lim, Paria et
al. 1997). COX2 inhibition in homozygous mice resulted in complete reproductive failure
(Reese, Zhao et al. 2001). Based on these information, we suspected that the impaired
fertility might come from reduced cellular senescence, since senescence has beneficial
effects in embryonic development and wound healing (McCulloch, Litherland et al.
2017), while our study suggests that COX activity is required to achieve senescence.
Besides, because of defective fertility of COX1 and/or COX2 mutant mice, we decided to
use an inducible COX2 KO mouse line in present study.
The inducible COX2 KO mouse was a kind gift from Dr. FitzGerald lab at the
University of Pennsylvania (Wang, Patel et al. 2009). In this mouse line, exons 6, 7, and
8, which are critical for enzyme activity, were flanked by 2 directly repeated loxP sites
inserted into the corresponding introns. Then, the mice were crossed into merCremer
mice under the α-myosin heavy chain promoter to permit tamoxifen-dependent deletion
of COX2 (Wang, Patel et al. 2009). DOX and tamoxifen treatment was according to
Figure 4.20. Briefly, 4 weeks after DOX treatment, mice were treated with tamoxifen to
induce COX2 knockout. The mouse phenotypes were analyzed 6 weeks after COX2
deletion.
Interestingly, COX2 deletion recused DOX-induced body weight loss (Figure
4.21 A). Monocyte is a type of white blood cell, and if functional parameters are
assessed, its number may approach 20% of the total white blood cell count (Zucker-
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Franklin 1974). The DOX-decreased monocyte population was also recovered by
tamoxifen treatment (Figure 4.22 A). These indicate that the DOX-induced aging
phenotypes can be at least partially recused by COX2 deletion, and the aging-rescuing
effect of aspirin indeed came from its COX inhibition activity.
Indeed, when aspirin was replaced by SC-236 (Figure 20), an selective COX2
inhibitor (Deleo, Hashizume et al. 2000), the same phenomenon could also be observed,
like rescued body weight and monocyte population (Figure 21 B and Figure 22 B),
further confirming that the aging-rescuing effect of aspirin we detected before was due to
COX inhibition.
Notably, compared to aspirin (Figure 4.9), both COX2 KO and SC-236 group had
less body weight gain, although this might come from different administration methods
between aspirin and tamoxifen/SC-236. While aspirin was dissolved in mouse-feeding
water, which was less harmful, both tamoxifen and SC-236 were administrated with
intraperitoneal injection, which could cause mice more stress. Additionally, tamoxifen
itself is a known toxin, inducing cell apoptosis and necroptosis (Kim, Amarnani et al.
2014), and mouse atrophy (Huh, Khurana et al. 2012). SC-236 was first dissolved in
DMSO and then water, making the final 5% DMSO solution, and DMSO was also known
to cause cell damage (Sperling and Larsen 1979), caspase-3 independent neuronal death
(Galvao, Davis et al. 2014), and apoptosis(Hanslick, Lau et al. 2009).
4.7 COX INHIBITORS AS NEW GENERATION OF SENOLYTIC DRUGS
Back in 2011, the senescence marker p16 was used to design a novel transgene
INK-ATTAC, for inducible elimination of p16 positive cells upon administration of
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AP20187 (Baker, Wijshake et al. 2011). Surprisingly, life-long removal of p16expressing cells delayed the onset of aging phenotypes like decreased muscle fiber size
and adipose tissue loss, and even attenuated progression of already established agerelated disorders like decreased adipocyte cell size and subdermal adipose layer
thickness. Remarkably, 8-month clearance of p16-expressing cell yielded no any
detectable overtly negative side effects (Baker, Wijshake et al. 2011). This encouraged
the usage of senescent cells as target of drugs which aimed at tissue rejuvenation and
aging prevention.
Up to date, several such drugs, which were called senolytic drugs, have been
developed, like quercetin, dasatinib (Zhu, Tchkonia et al. 2016), ABT263 (Chang, Wang
et al. 2016), ABT737 (Yosef, Pilpel et al. 2016), FOXO4-DRI (Baar, Brandt et al. 2017).
But they were either non-specific or not FDA-approved, which prevented their quick
therapeutic use. NASIDs are the most frequently consumed drugs worldwide (Frolich
1997), and most of them are already FDA-approved. What’s more, long term usage of
NASIDs like aspirin has even been reported with positive effects like prolonged lifespan
(Vane and Botting 2003), indicating that NASIDs’ long term usage is acceptable and
safe. Since the administration of COX inhibitors like aspirin partially recovered aging
phenotypes through elimination of senescent cells, we wondered that if NASIDs could be
developed as a new generation of senolytic drugs.
To test this, WI38 human fibroblast cells were first treated with DOX to induce
senescence, and then various concentrations of aspirin and sulindac, another COX
inhibitor known to inhibit both COX1 and COX2 (Oshima, Dinchuk et al. 1996), were
applied. As expected, the viability of senescent WI38 cells were sharply decreased in a
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dose-dependent manner by both sulindac and aspirin (Figure 4.23), indicating that indeed
NASIDs have senolytic potential.
In order to test if the clearance effect of NASIDs is senescent cell-specific, SA-βgal assay was performed. As cell proliferation capability is reduced and cell growth
arrested, fibroblasts acquire a drastically different morphology compared to control cells,
appearing considerably larger in size, flatter, less contrasted, and more adhesive to the
per-nuclear area (Anastasia, Sampaolesi et al. 2006, Piccoli, Palazzolo et al. 2012). While
fibroblasts in the control group were flatter and less contrasted, indicating reduced
proliferation capability and cell growth arrest due to DOX treatment, the remaining
fibroblasts in NASID groups, especially 5mM aspirin, exhibited spindle morphology
characteristic of low cumulative population doubling proliferating fibroblasts (Walters,
Deneka-Hannemann et al. 2016), suggesting increased activity and growth (Figure 4.24).
While senescent cell viability was decreased (Figure 4.24), senescent cell population
percentage was also significantly decreased in total cell population (Figure 4.25), after
the administration of either sulindac or aspirin, indicating that the COX inhibitors
targeted senescent cell specifically.
Cellular senescence requires two factors: cell cycle arrest caused by p53 and
simultaneous activation of the mTOR signaling (Korotchkina, Leontieva et al. 2010). p70
can be directly phosphorylated and activated by mTOR (Hara, Yonezawa et al. 1998,
Isotani, Hara et al. 1999), which has been reported recently as critical to the survival of
senescent cells (Korotchkina, Leontieva et al. 2010). pan-mTOR inhibition by TORspecific ATP mimetic AZD8055 was recently found to have cellular senescence reversal
capability (Walters, Deneka-Hannemann et al. 2016). The enhanced mTOR signaling has
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also been detected in aged tissues (Nacarelli, Azar et al. 2015), while caloric restriction,
which has been known to decelerate aging, also deactivated mTOR pathway
(Blagosklonny 2010). Additionally, c-Jun N-terminal kinase (JNK), has been reported
with senescence suppression role (Lee, Lee et al. 2010). Therefore, we checked p70
phosphorylation level on threonine 389 and JNK from senescent WI38 cells with or
without COX inhibitors. Western blot results showed that both sulindac and aspirin
inhibited p70 phosphorylation level dose-dependently (Figure 4.26 A), indicating that the
senescent cell clearance effect of NASIDs might come from inhibition of mTOR/p70
signaling. Also, both sulindac and aspirin up-regulated JNK protein level (Figure 4.26 B),
suggesting that NASID might also upregulate JNK in order to perform senescent cell
clearance activity.
Phosphorylation of p70 negatively regulates autophagosome formation and
autophagic proteolysis (Blommaart, Luiken et al. 1995, Hara, Yonezawa et al. 1998).
Thus, we wondered if the cell death induced by NASIDs came from enhanced autophagy.
The membrane-bound microtubule-associated protein chain 3 (LC3) is one of the most
specific biomarkers of autophagy, and in mammals, LC3 is expressed in three isoforms,
a, b, and c. The b form, LC3b, has broad tissue specificities and is widely used as marker
in autophagy-related studies (Chen, Jiang et al. 2013). Western blot result shows that
LC3b protein level was sharply decreased with NASIDs administration, indicating that
the cell death induced through COX inhibition may be autophagy-independent (Figure
4.26 A). This is in accordance with Figure 4.6 and 4.7, that COX2 KO or inhibition
suppressed p53 and p21 signaling, since both p53 (Korotchkina, Leontieva et al. 2010)
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and p21 (Capparelli, Chiavarina et al. 2012) has been reported with autophagy
stimulation activity.
Additionally, as senescent MRC5 human lung fibroblasts, induced by DOX, were
treated with aspirin or celecoxib, a selective COX2 inhibitor (Goldstein, Silverstein et al.
2000), cell viability was also significantly decreased (4.27 A). The B-cell lymphoma 2
(Bcl-2) protein family, including Bcl-xL, plays an important role in regulating intrinsic
apoptotic signaling pathway (Scherr, Gdynia et al. 2016). Directed Bcl-xL inhibition by
siRNA or small molecule ABT-737 could eliminate senescent cells (Yosef, Pilpel et al.
2016). Interestingly, the Bcl-xL protein level was also greatly decreased with either
aspirin or celecoxib administration (Figure 4.27 B), indicating that NASIDs possibly also
eliminate senescent cells through Bcl-xL inhibition.
In summary, DOX administration increased COX2 expression, and COX2
deletion could suppress this COX2 induction. Both in vitro and in vivo, COX inhibition
could induce elimination of senescent cells and partially rescue DOX-induced aging
phenotypes, possibly through the suppression of p70 and Bcl-xL pathway.
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Figure 4.1 COX2 expression increased in tissues of DOX-treated mice. DOX
treatment increased COX2 protein level in skin (A), liver (B), inguinal fat (C), and
thymus (D). Protein lysates were made from sonicated tissues (skin, liver, inguinal fat,
or thymus) from mice treated with either PBS or DOX, in RIPA buffer containing
HaltTM Protease Inhibitor Cocktail. COX2, actin, and GAP-DH proteins were probed
with anti-COX2, anti-actin, and anti-GAP-DH primary antibody, respectively.
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Figure 4.2 Western blot analysis for COX2 in wild-type and COX2 knockout MEFs.
Protein lysates were made in RIPA Buffer containing HaltTM Protease Inhibitor
Cocktail. COX2 protein was probed with anti-COX2 antibody.
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Figure 4.3 COX2 deletion reduced DOX-induced senescence. MEFs were treated with
either DMSO (control) or 1mM DOX for 2h, and SA-β-gal staining assay was
performed to detect cellular senescence. (A) Representative photographs of SA-β-gal
assay after DOX treatment of MEF WT and MEF CO2 KO cells. (B) COX2 deletion
reduced SA-β-gal-positive cell percentage.
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Figure 4.4 Transgenic expression of COX2 increases p53 level in vivo. Western blot
analysis of COX2 and p53 in pancreas, skin, and muscle tissues of control and COX2
transgenic littermates.
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Figure 4.5 p53 and p21 expression in tissues of DX-treated mice. DX treatment
increased COX2 protein level in skin (A), liver (B), inguinal fat (C), thymus (D),
testicle (E), and lung (F). Protein lysates were made from sonicated tissues (skin,
liver, inguinal fat, or thymus) from mice treated with either DX or PBS, in RIPA
buffer containing HaltTM Protease Inhibitor Cocktail. COX2, actin, and GAP-DH
proteins were probed with anti-COX2, anti-actin, and anti-GAP-DH primary antibody,
respectively.
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Figure 4.6 COX2 suppression decreased p53 level upon DOX treatment. WI38 cells
were treated with PBS/1mM DOX for 2h, with or without COX inhibitors, and protein
lysates were made in RIPA buffer containing HaltTM Protease Inhibitor Cocktail.
COX2, p53 and GAP-DH protein were probed with the antibody of each. The final
concentration of each inhibitor: DuP-697 5µM, aspirin 1µM, celecoxib 2.5µM, and
piroxicam 20µM.
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Figure 4.7 COX2 deletion decreased p53 level upon DOX treatment. MEF WT and
COX2 KO MEFs were treated with 1mM DOX for 2h, and protein lysates were made.
COX2, p53, p21, and GAP-DH protein were probed with the antibody of each.
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Figure 4.8 Pharmacological treatment procedure of C57BL/6 with DOX and aspirin.
2.5mg/kg DOX was intraperitoneally injected four times into C57BL/6 mice when the
mouse was 2, 3, 4, and 5-week-old. Then mice were fed with 0.02g/100mL aspirin
water after they were 9-week-old. Various tissues were harvested when the mouse was
16~18-week-old.
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Figure 4.9 Aspirin partially recovered DOX-caused body weight loss and white blood
cell (WBC) loss. body weight gain (A) and WBC cell counts (B) were determined.
(n=4)
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Figure 4.10 Aspirin partially recovered DOX-induced inguinal fat loss. (A) A
representative photograph of inguinal fats (Arrows) after PBS (Control), DOX and/or
aspirin treatment. (B) A representative photograph of isolated inguinal fats after PBS
(Control), DOX and/or aspirin treatment. (C) Aspirin treatment partially rescued
DOX-decreased inguinal fat weight/body weight ratio (n=4).
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Figure 4.11 Aspirin partially recovered DOX-induced epididymal fat loss. (A) A
representative photograph of epididymal fats (Arrows) after PBS (Control), DOX
and/or aspirin treatment. (B) A representative photograph of isolated epididymal fats
after PBS (Control), DOX and/or aspirin treatment. (C) Aspirin treatment partially
rescued DOX-decreased epididymal fat weight/body weight ratio (n=4).

67

Figure 4.12 Aspirin partially rescued DOX-induced sperm population decrease.
Representative photographs of testicle H&E-stained sections after PBS (Control),
DOX and/or aspirin treatment.
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Figure 4.13 Aspirin partially recovered DOX-induced tissue weight loss. Tissue
weight/body weight ratio was partially rescued by aspirin in brown adipose tissue (A),
testicle (B), and lung (C). n=4.
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Figure 4.14 Aspirin partially recovered DOX-induced subcutaneous fat loss. Scale bar
= 100µm. (A) Representative photographs of skin H&E-stained sections after PBS
(Control), DOX, and/or aspirin treatment. (B) Subcutaneous fat decreased after PBS
(Control), DOX, and/or aspirin treatment (n=6). The skin sample was embedded into
paraffin block and sectioned into 5µm sections. Sections were stained with
hematoxylin and eosin after 1h baking at 60°C within hybridization oven.
Subcutaneous fat width was measured with ImageJ.
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Figure 4.15 Aspirin partially recovered DOX-induced muscle fiber size decrease. (A)
H&E stained sections of hind leg skeletal muscle from PBS (Control), DOX, and/or
aspirin-treated male littermate. (B) Frequency distribution of skeletal muscle fiber
cross-sectional area (CSA) between PBS (Control), DOX, and/or aspirin-treated male
mice. Scale bar = 100µm.
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Figure 4.16 Aspirin partially recovered DOX-induced fat loss. Representative
photographs of H&E stained sections of inguinal fat after PBS (Control), DOX, and/or
aspirin treatment.
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Figure 4.17 Aspirin partially recovered DOX-induced necrosis in mouse brain. (A)
Representative photographs of H&E stained sections of brain after PBS (Control),
DOX, and/or aspirin treatment. (B) Necrotic neuron counting in 250µm2. While DOX
increased necrotic neuron number, aspirin treatment restored neuron necrosis level.
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Figure 4.18 DOX-induced cellular senescence was partially rescued by aspirin.
Aspirin recovered DOX-induced cellular senescence in liver (A), spleen (B), pancreas
(C), and lung (D) in vivo. Mice were sacrificed, and tissues were immediately
harvested and embedded in O.C.T. Compound. Cryosections were made from
embedded samples, and SA-β-gal in vivo assay was performed.
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Figure 4.19 Aspirin recovered DOX-induced the mRNA level of cellular senescence
markers, p16 and IL6. p16 and IL6 mRNA levels were determined by real-time
quantitative PCR. The DOX-induced p16 level was restored by aspirin treatment in
liver (A), inguinal fat (B), and spleen (C). The DOX-induced IL6 level was restored
by aspirin treatment in spleen (D), and liver (E).

75

Figure 4.20 Treatment schedule for COX2 knockout induction and SC-236.
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Figure 4.21 COX2 deletion or selective pharmacological inhibition recovered DOXinduced body weight loss. (A) COX2 knock-out recovered body weight loss under
DOX treatment. (B) SC-236, a COX2 specific inhibitor, recovered body weight loss
under DOX treatment. n=3.
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Figure 4.22 COX2 deletion or selective pharmacological inhibition recovered
monocyte population level under DOX treatment. (A) COX2 knock-out recovered
monocyte population decrease under DOX treatment. (B) SC-236, a COX2 specific
inhibitor, also recovered monocyte population decrease under DOX treatment. n=3.
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Figure 4.23 NSAIDs reduced viability of senescent WI38 cells. (A) Senescent WI38
cell viability was reduced after 100µM and 200µM sulindac treatment; (B) Senescent
WI38 cell viability was reduced after 1mM, 2.5Mm and 5mM aspirin treatment. Cell
viability was analyzed by MTT assay.
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Figure 4.24 NSAIDs decreased cellular senescence level. (A) Representative
photographs of senescent level decrease, and cell morphology change, after sulindac
(100µM and 200µM) and aspirin (1mM, 2.5mM and 5mM) treatment. (B)
Representative cell culture well photographs of SA-β-gal-positive cell number
generally decreased after sulindac (100µM and 200µM) and aspirin (1mM, 2.5mM
and 5mM) treatment.
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Figure 4.25 NSAIDs decreased percentage of senescent cells. SA-β-gal-positive
population decreased after sulindac (100µM and 200µM) and aspirin (1mM, 2.5mM
and 5mM) treatment.
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Figure 4.26 NSAIDs decreased p70, JNK, and LC3b signaling level in senescent
WI38 cells. (A) p-p70 and LC3B protein level decreased after sulindac (100µM and
200µM) and aspirin (1mM, 2.5mM and 5mM) treatment, while total p70 protein level
was generally unchanged. (B) Total JNK protein level increased after sulindac
(100µM and 200µM) and aspirin (1mM, 2.5mM and 5mM) treatment.
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Figure 4.27 Bcl-xL signaling was decreased after treatment of COX inhibitors. (A)
DOX-induced senescent MRC5 cells were treated with aspirin (1 mM) or celecoxib
(20µM) for 12 days. Treated cells were stained with Calcein AM and DAPI for
visualization of live and dead cells, respectively. Data are presented as the percent of
live cells. (B) Western blot analysis of Bcl-xL in senescent MRC5 cells treated with
1mM aspirin and 20 µM celecoxib for 72 hours.
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CHAPTER 5
DISCUSSION
Increasing evidence has implicated the role of COX2 in aging. Neonatal death and
renal pathology in global COX2 knockout mice prevents them from being used to study
the role of COX2 in the aging process (Loftin, Trivedi et al. 2001). We have developed a
COX2 transgenic mouse model which allows conditional, tissue-specific COX2
expression (Shim, Foley et al. 2010). Using this model, we have generated tamoxifeninducible COX2 transgenic mice to investigate the biological significance of COX2 upregulation during aging. When COX2 expression was induced in 5~6-week-old mice,
COX2 transgenic mice developed various signs of aging such as reduced subcutaneous
fat, delayed hair growth, chronic pancreatitis, infertility, and decreased muscle fiber size.
In addition, the lifespan of COX2 transgenic mice was significantly reduced compared to
that of wild type littermates. All COX2 transgenic mice exhibited at least some of these
phenotypes characteristic of premature aging, implicating COX2 as a potential target in
the control of age-related diseases.
Aging phenotypes observed in other models, such as liver pathologies and
kyphosis were not observed in our COX2 transgenic model. This may be related to a low
level of COX2 transgene expression in these tissues. If this is the case, then it suggests
that the effect of COX2 may be mediated by local production of prostanoids.
Alternatively, COX2 may differentially affect the physiology of these tissues. For
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example, prostaglandin E2 (PGE2), a major prostanoid produced by COX2, is a strong
inducer of bone formation in a variety of animals (Norrdin, Jee et al. 1990), including
humans. In addition, COX2 has been shown to regulate mesenchymal cell differentiation
into osteoblast lineage (Zhang, Schwarz et al. 2002). We have also recently shown that
prostaglandin F2α (PGF2α) stimulates chondrocyte differentiation and promotes bone
morphogenetic protein (BMP) signaling (Kim and Shim 2015). Thus, increased
expression of COX2 may protect the skeleton from age-associated damage such as
osteoporosis, which is frequently observed in other mouse models of aging. COX2 has
been implicated in inflammatory and degenerative brain diseases (Minghetti 2004). In the
current study, brain aging in COX2 transgenic animals was not analyzed. However, it has
been shown that neuronal-specific COX2 transgenic mice develop age-dependent
cognitive deficits and neuronal apoptosis (Andreasson, Savonenko et al. 2001),
suggesting that COX2 also contributes to neuronal aging. Moreover, Mirjany et al.
(Mirjany, Ho et al. 2002) have shown that COX2 accelerates glutamate-induced apoptotic
damage in neuronal-specific COX2 transgenic mice.
It is well-known that COX2 plays an important role in inflammation. Chronic
inflammation is a hallmark of cellular senescence and aging, and promotes many agerelated diseases (Franceschi, Capri et al. 2007). It has been shown that knockout of the
nfkb1 subunit of the transcription factor NFκB causes chronic inflammation and
accelerated aging (Jurk, Wilson et al. 2014). In the same study, ibuprofen, a general COX
inhibitor, reduced inflammation and restored regenerative capacity of hepatocytes in
nfkb1-/- mice. However, although COX2 expression caused pancreatitis in our COX2
transgenic model, the signs of chronic inflammation such as increased tissue infiltration
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of immune cells and elevated levels of inflammatory cytokines were not observed. This
suggests that chronic inflammation may not be the mechanism by which COX2 regulates
the aging process. Currently, how COX2 induces aging phenotypes is not clear. At the
cellular level, COX2 inhibitors suppressed the replicative senescence, while PGE2
promoted cellular senescence (Han, Roh et al. 2004, Martien, Pluquet et al. 2013, Chou,
Ramirez et al. 2014), suggesting the involvement of prostaglandins and their receptors in
cellular senescence. However, another study has shown that celecoxib, a COX2 specific
inhibitor, extends the life span of C. elegans and delays the age-associated physiological
changes via inhibition of insulin-like signaling, but not via COX2 activity (Ching, Chiang
et al. 2011). On the other hand, a mouse study has shown that generation of reactive
oxygen species (ROS) increases with age, which may result from increased COX2
expression and activity in aged animals (Kim, Kim et al. 2000). In our study, signaling
pathways involving p53 might play a role in COX2-induced senescence and aging, but
the exact mechanism still needs further study.
Late effects, which resembles early aging phenotypes, are a profound concern of
childhood cancer survivors (Larsen, Muller et al. 2003, Armstrong, Kawashima et al.
2014). Around 200,000 children of the world develop cancer each year, and it was
estimated that the total number childhood cancer survivors was around 220,000 in the
United States in the year of 2000 (Bleyer 1990). With age, the risks of late effects in
childhood cancer survivors are increasing, requiring the imminent need of effective
therapy to alleviate these early aging phenotypes. In our study, we developed a mouse
model of chemotherapy-induced aging of childhood cancer survivors, with common
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chemotherapeutic agent DOX. Our mouse model developed aging phenotypes like
reduced reproductive ability, decreased fat amount and muscle atrophy.
Chemotherapy-related mouse models have been developed by many groups, like
mouse model developed with paclitaxel, a chemotherapeutic agent known to have
neurotoxic properties, to study chemotherapy-related fatigue (Ray, Trammell et al. 2011),
mouse model developed with DOX for the same purpose (Zombeck, Fey et al. 2013),
mouse model of gastric cancer with intravoxel incoherent motion diffusion-weighted
magnetic resonance imaging to study chemotherapy response evaluation (Cheng, Wang
et al. 2017), among others. However, all these models were developed from adult mouse,
making them inappropriate to study the long-term late effects of chemotherapy in
childhood cancer survivors. Therefore, our mouse model, developed from juvenile mice
fulfills this imminent need.
COX2 pathway has been known to maintain senescence and inflammation of
fibroblasts (Zdanov, Bernard et al. 2007, Dagouassat, Gagliolo et al. 2013). But COX2
inhibitors, although have been observed with a role in senescence and aging, were
proposed that this was due to its catalytic activity-independent manner (Kim, Park et al.
2008, Lee, Kim et al. 2012). In present study, we confirmed that COX2 played an
essential role in maintaining cellular senescence. COX2 inhibitors, either non-selective
like aspirin and sulindac, or selective like SC-236 and celecoxib, induced elimination of
senescent cells both in vitro and in vivo, and in this way alleviated early aging
phenotypes induced by chemotherapeutic agent like DOX.
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The mTOR is a serine/threonine kinase responsible for nutrients integration to
execute cell growth and division (Kim and Guan 2015, Barilari, Bonfils et al. 2017). This
kinase exists in two complexes of mTORC1 contain RAPTOR and mTORC2 containing
RICTOR (Kim and Guan 2015, Ito, Yurube et al. 2017). Downstream effectors of
mTORC1 including p70 regulate cell proliferation, mRNA translation, and protein
synthesis (Ito, Yurube et al. 2017). Recently, mTOR signaling has been shown to
promote cellular senescence and aging in various model organisms, and in mice,
inhibiting mTOR by rapamycin treatment can significantly extend lifespan and many
age-related diseases (Xu, Cai et al. 2014, Weichhart 2018). Besides, persistent mTOR
signaling supports senescent cell survival, suggesting manipulating it signaling pathway
could be a promising way to induce cell death of senescent cells (Carroll, Nelson et al.
2017). The p70 kinase activity is regulated by many phosphorylation events on amino
acids within the catalytic and linker domains. Among these, Thr229 phosphorylation in
the catalytic domain and Thr389 phosphorylation in the linker domains are most
important for kinase function (Pullen and Thomas 1997), while phosphorylation of
Thr389 is most closely related with this enzyme’s in vivo activity (Weng, Kozlowski et
al. 1998). Environmental stresses like ultraviolet (UV) has been reported to induce
phosphorylation of p70 at Thr389 site (Huang, Li et al. 2002). Earlier phosphorylation of
Thr389 is also required for the action of phosphoinositide 3-dependent protein kinase 1
on Thr229 (Alessi, Kozlowski et al. 1998, Pullen, Dennis et al. 1998). In present study,
we showed decreased p70 phosphorylation level at Thr389 in senescent cells after
NSAID treatment, indicating decreased p70 kinase activity, and NSAIDs eliminate
senescent cells possibly through suppressing this signaling pathway.
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Autophagy is the major cellular digestion process that removes damaged
macromolecules and organelles (Kim and Guan 2015), through which a portion of the
cytoplasm is delivered to lysosomes to be degraded (Kuma, Matsui et al. 2007). mTOR,
as a central regulator of cell growth, plays a key role at the interface of pathways that
coordinately regulate the balance between cell growth and autophagy in response
nutritional status, growth factors and stress signals (Jung, Ro et al. 2010). Autophagy
induction by genetic or pharmacologic inhibition of mTOR has been reported in many
organisms like yeast, Drosophila, and mammalian cells (Kim and Guan 2015). Therefore,
we wondered if the induced senescent cell death by NASIDs was due to increased
autophagy level. Microtuble-associated protein light chain 3s (LC3s) are structural
proteins of autophagosomal membranes, and the human LC3 family has three mambers
LC3a, LC3b, and LC3c (Koukourakis, Kalamida et al. 2015). While LC3b has been
proposed as ideal marker for monitoring autophagy level (Schlafli, Berezowska et al.
2015), its protein level after NSAID treatments was surprisingly decreased. While it is
unclear so far about the mechanism of this phenomenon, LC3b’s decrease with NSAID
treatments suggests it is unlikely that NSAIDs promote cell death of senescent cells
through autophagy induction.
p53 is known to play a pivotal role in cellular homeostasis; thus, dysregulation of
p53 signaling is linked to aging or to the development of diseases such as cancer.
Expression of p53 is induced by various cellular or environmental stimuli. Intriguingly,
many signals that activate p53 are known to induce COX2 expression as well (de Moraes,
Dar et al. 2007), suggesting the existence of cross-talk between these two pathways. It is
well-known that p53, as a transcription factor, positively or negatively regulates COX2
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expression. However, the role of COX2 as an upstream regulator of p53 has not been
well-studied. We previously have demonstrated that COX2 positively regulates p53
levels (Ventura, Kirsch et al. 2007). In COX2 transgenic embryos which develop severe
axial skeletal malformations, accumulation of p53 protein was dramatically increased in
the precursor cells of the axial skeleton, indicating that COX2 functions as an upstream
regulator of p53 signaling. Moreover, we recently have shown that doxorubicin-induced
p53 expression is reduced by inhibition or knockdown of COX2, further supporting the
role of COX2 in regulating p53 (Kim and Shim 2016). Although the underlying
mechanism by which COX2 causes elevated levels of p53 warrants further study,
previous reports suggested that COX2 can regulate p53 through prostaglandin -dependent
and -independent mechanisms. For example, it has been shown that PGE2 stimulates p53
activity in human synovial fibroblasts through p38 kinase-mediated phosphorylation of
p53 (Faour, He et al. 2006). Additionally, PGE2 has been shown to be involved in p53
activation and maintenance of the senescent phenotype in chronic obstructive pulmonary
disease (COPD) fibroblasts (Dagouassat, Gagliolo et al. 2013). On the other hand, COX2
has been shown to induce genomic instability (Singh, Cook et al. 2008) and generate
reactive oxygen species (Xu, Choudhary et al. 2006) in a prostaglandin-independent
manner. In the current study, p53 expression was up-regulated in the tissues of COX2
transgenic mice, suggesting that COX2-mediated p53 activation may contribute to
premature aging phenotype. Future study with p53 null mice will determine whether
aging-phenotypes in COX2 transgenic mice are p53-dependent. Likewise, both COX2
and p53 expression was also up-regulated in tissues of DOX-treated mice, indicating that
COX2 plays a role in chemotherapy-induced early aging phenotypes, possibly through
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p53 induction. Additionally, activation of p53 inhibits mTOR activity, and regulates its
downstream targets like p70 Thr389 phosphorylation level and autophagy (Feng, Zhang
et al. 2005). However the decreased p50 and p70 Thr389 phosphorylation after NSAIDs
treatment suggest that the decreased p70 phosphorylation level in our study is not likely
regulated by p53, which was up-regulated after DOX administration.
It has long been known that accumulation senescent cells promote aging and agerelated diseases. In 2011, a study using transgenic mice reported that clearance of p18positive senescent cells could prevent or delay age-related tissue dysfunction and extend
healthspan (Baker, Wijshake et al. 2011). Since then, various methods have been
developed to induce cell death of senescent cells, in order to eliminate them from
nontransgnic organisms to improve healthspan. Among them, inhibiting Bcl-xL activity
with siRNAs or small molecule ABT-737 has been shown as an effective way. The Bcl2
protein family, including Bcl-xL, is mainly known for its pivotal role in the regulation of
the mitochondrial death pathway (Scherr, Gdynia et al. 2016). Under physiological
conditions, pro-apoptotic members like Bax and Bak are sequestered and thereby
inhibited by anti-apoptotic relative like Bcl-xL. If apoptotic stimuli like DNA damage
occur, pro-apoptotic proteins get released from their binding, leading to subsequent
mitochondrial activation and initiation of the downstream apoptosis cascade (Cory and
Adams 2002, Scherr, Gdynia et al. 2016). Here we show that NSAIDs could reduce BclxL protein level. This indicates that NSAIDs may initiate cell death of senescent cells by
releasing pro-apoptotic proteins through both p70 and Bcl-xL signaling inhibiton. In
support to this, co-targeting Bcl2 and mTOR-p70 pathway has also been reported
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recently as an effective way to trigger synergistic apoptosis (Iacovelli, Ricciardi et al.
2015).
Each available senolytic drugs so far has critical disadvantage to prevent it from
immediate usage: Quercetin, ABT263/737 and FOXO4-DRI are not FDA-approved, and
while quercetin, dasatinib, ABT263/737 are non-specific (Zhu, Tchkonia et al. 2016,
Baar, Brandt et al. 2017). NSAIDs used in this study have been FDA-approved and
showed specificity toward senescent cells. With this we propose NSAIDs like aspirin,
have strongly promising potential to be developed as a new generation of senolytic drugs
to induce senescent cell elimation.
COX2 expression is increased in many age-related human diseases and in the
tissues of aged humans and mice, implicating the involvement of COX2 in the aging
process. However, the biological significance of increased COX2 expression during
aging has not been determined. Our data suggest that targeting of COX2 and its
downstream pathways may have therapeutic and preventive potential against aging and
age-related diseases. In summary, we first found that COX2 overexpression in mice
caused increased cellular senescence and aging phenotypes. DOX treatment was also
discovered with induction effect on cellular senescence and aging. Importantly, DOX
administration also caused increased COX2 expression, and COX2 deletion antagonized
cellular senescence level, indicating DOX induces aging through elevated cellular
senescence, which is mediated by COX activity. Therefore, we tried to manipulate COX
level to rescued cellular senescence and aging. As result, COX inhibitors successfully
decreased senescence level, and aging phenotypes caused by DOX administration,
possibly through suppression of p70 and Bcl-xL signaling. Our study indicates that COX
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inhibitors, or NASIDs, can be developed as new generation of senolytic drugs to reduce
late effects of chemotherapy and improve healthspan.
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CHAPTER 6
MATERIALS AND METHODS
6.1 GENERATION OF COX2 TRANSGENIC MICE
All animal studies and procedures were approved by the University of South
Carolina Institutional Animal Care and Use Committee. The transgenic basic cassette,
pCAG-CAT-HES-poly(A), was a gift from Dr. Junichi Miyazaki (Osaka University
Medical School, Japan). Human COX2 cDNA was inserted into HindIII and EcoRV sites
of pCAG-CAT-HES-poly(A). The transgenic vector was digested with SalI and PstI to
remove the vector region. The insert fragment was recovered from the gel and diluted to
2μg/ml concentration in 1 mM Tris/HCl (pH 8.0) and 0.1mM EDTA. The DNA fragment
was introduced into pronuclei of 0.5-day-old mouse embryos (B6D2F1, Taconic) by
glass capillaries. Injected embryos were cultured in KSOM (Sigma) for 1 day, and
embryos that reached the two-cell stage were transferred into oviducts of pseudopregnant
females. The offspring was initially screened by PCR for the chloramphenicol
acetyltransferase (CAT) gene from tail tissue (CAT2 primer, 5’CAGTCAGTTGCTCAATGTACC-3’; CAT3 primer, 5’-ACTGGTGAAACTCACCCA3’). For production of the CATflCOX2 mice, five lines were initially established, and two
of them, lines 12 and 17, showing high CAT activity in the liver, were chosen for further
analysis. ROSA-Cre ERT2 mice were obtained from the Jackson Laboratory. A ROSA-
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Cre ERT2 female (or CATflCOX2 female) mouse was housed overnight with a
CATflCOX2 male (or ROSACre ERT2 male) mouse.
6.2 GENOTYPING AND PHARMACOLOGICAL TREATMENT OF MICE
Genomic DNA was isolated from tails using a DNeasy kit (Qiagen). Isolated
genomic DNA was amplified using ExTaq DNA polymerase (Takara) with a primer set
designed to detect the presence of a recombined human COX2 allele (forward primer, 5’GTGCTGGTTATTGTGCTGTCTC-3’; reverse primer, 5’TCTCCATAGAATCCTGTCCGGGTA-3’), and PCR products were run on 1.2%
agarose gel. The recombined human COX2 allele was identified as a 300 bp PCR
product, whereas the non-recombined human COX2 allele was identified as a 1.8 kb
fragment. To detect the presence of the Cre gene, genomic DNA was amplified by PCR
using a primer set for Cre (forward primer, 5’-ACCTGAAGATGTTCGCGATTATCT3’; reverse primer, 5’-ACCGTCAGTACGTGAGATATCTT-3’).
In order to induce COX2 expression, 100μl of tamoxifen (10mg/ml in corn oil)
was intraperitoneally injected every 3 days, for a total of three times, to 5-week-old
control (wild type, CATflCOX2, or Rosa-CreERT2) and transgenic (CATflCOX2:RosaCreERT2) mice. Aspirin treatment was administrated to mice by dissolving aspirin
(Sigma-Aldrich, St. Louis, MO) (0.025mg/mL) in feeding sterile water. SC-236 was first
dissolved in DMSO, and then in water. Mice were intraperitoneally injected with SC-236
at concentration 2mg/kg, every 3 days for 2 weeks (total injection 5).
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6.3 HISTOLOGY AND IMMUNOHISTOCHEMISTRY
Mouse tissues were collected, fixed in 10% neutral buffered formalin, and
embedded in paraffin blocks. Tissue sections (5μm) were subjected to hematoxylin-eosin
(H&E) staining by standard procedures. For immunohistochemical analysis, antigen
retrieval was performed by immersing sections in 10mM sodium citrate (pH 6.0) at 95°C
for 30 min. Sections were incubated with primary antibody [human COX2 (1:500),
Cayman Chemical; p16 (1:500), Santa Cruz Biotechnology; cleaved caspase-3 (1:250),
Cell Signaling] at 4°C overnight. For detection of p-H2AX, sections were subjected to
EDTA (1mM, pH 8.0) antigen retrieval for 20 min and incubated with primary antibody
[p-H2AX (Ser139) (1:500), Cell Signaling] at 4 °C overnight. Washed sections were
incubated in the ImmPress reagent (Vector Laboratories) for 30 min and visualized with
diaminobenzidine. After mounting, the sections were observed under an Oympus BX51
light microscope, and the image was acquired by an AxioCam MRc camera. For
cryosections, freshly harvested tissues were imbedded into Tissue-Tek O.C.T. Compound
(Sakura Finetek USA Inc. Torrance, CA), and sections were made at 5μm.
6.4 ISOLATION OF MOUSE LUNG FIBROBLASTS AND SA-Β-GALACTOSE IN
VITRO STAINING
Isolation of adult mouse lung fibroblasts from control and transgenic mice was
carried out as described (Seluanov, Vaidya et al. 2010). For SA-β-galactose staining, 5 x
105 fibroblasts were plated in 60 mm culture dishes, and incubated with 1µM 4hydroxytamoxifen (Sigma) for 24 hours. Forty eight hours after 4-hydroxytamoxifen
treatment, the cells were fixed in 2% formaldehyde/0.2% glutaraldehyde, washed with
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phosphate-buffered saline, and incubated at 37°C overnight in stain solution [1mg/ml 5bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 40mM citric acid-sodium
phosphate (pH 6.0), 150mM NaCl, 2mM MgCl2, 5mM potassium ferrocyanide, 5mM
potassium ferricyanide].
6.5 CELL CULTURE
WI38 and MRC5 cells were obtained from the American Type Culture Collection
(ATCC), and were grown in regular cell culture medium (DMEM supplemented with
10% BS and gentamycin). 0.25x106 cells were plated in 35mm cell culture dish. 24 hours
later, cells were treated with 1mM doxorubicin for 2 hours, washed with sterile
phosphate-buffered saline (PBS), and replaced with fresh cell culture medium. 72 hours
later, cells were treated with various concentrations of NASIDs.
6.6 WESTERN BLOT ANALYSIS
Cells were washed with cold PBS, and lysed on ice in modified RIPA buffer
(50mM Tris-HCl, pH 7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 1mM Na3VO4,
10mM NaPPi, 10mM glycerophosphate and 50mM NaF) supplemented with the Halt
protease inhibitor cocktail (Thermo Scientific). Tissues were also lysed in RIPA buffer,
and protein concentration was measured using a BCA protein assay kit (Pierce). Equal
amounts of protein were heated at 65 °C in LDS sample buffer (Invitrogen) with sample
reducing agent (Invitrogen) for 10 min and then separated by SDS-PAGE. The separated
proteins were transferred to an Immobilon-P membrane (Millipore). Following
incubation in blocking buffer (TBS with 5% nonfat dry milk and 0.1% Tween 20) for 1
hour at room temperature, the membranes were incubated with primary antibodies [p53
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(1:2000), Cell Signaling; GAP-DH (1:5000), Cell Signaling; human COX2 (1:500),
Cayman Chemical] diluted in blocking buffer overnight at 4°C. The membranes were
washed and then probed with a horseradish peroxidase-linked secondary antibody (Cell
Signaling) for 1 hour at room temperature. Detection was made with an enhanced
chemiluminescence reagent (GE Healthcare Life Sciences), followed by exposure of
membrane to film.
6.7 REAL-TIME PCR
RNA was isolated using an RNeasy kit (Qiagen) and treated with 1 unit of
amplification grade DNase I (Invitrogen) per 1µg RNA at room temperature for 15min to
remove genomic DNA followed by inactivation of the DNase I with 2.5mM EDTA (pH
8.0) and incubation at 65°C for 5min. Reverse transcription was done with 2µg total RNA
using SuperScript II reverse transcription system (Invitrogen) according to the
manufacturer’s instructions. Quantitative real-time PCR analysis was conducted using a
GoTaq® qRCR mixture (Promega). Reactions were run in triplicate for three independent
experiments. The mean of housekeeping gene GAP-DH was used as an internal control to
normalize the variability in expression levels. Expression data were normalized to the
mean of GAP-DH to control the variability in expression levels and were analyzed using
the 2-ΔΔCT method.
6.8 MTT ASSAY
0.09x106 cells were plated to each well of 96-well plate, together with 100µL cell
culture medium. 24 hours later, cells were treated with 1mM doxorubicin for 2 hours,
washed with sterile phosphate-buffered saline (PBS), and replaced with fresh cell culture
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medium. 72 hours later, cells were treated with various concentrations of NASIDs. To
measure cell viability, 20µL 5mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO), dissolved in PBS,
was added to each well. Plate was incubated for 2.5 hours in 37°C. Then culture medium
was replaced with 150µL DMSO in each well, and plate was kept in the dark on The
Belly Dancer (Stovall Life Science Inc., Greensboro, NC) for 20min. Each well of the
plate was read under absorbance of 490nm by Synergy HT microplate reader (BioTek
Instruments, Inc., Winooski VT).
6.9 SA-B-GAL IN VIVO ASSAY
Cryosections were first rinsed with PBS, and then fixed with G/F fixative solution
[0.2% glutaraldehyde (Sigma-Aldrich, St. Louis, MO), 1.85% formaldehyde (SigmaAldrich, St. Louis, MO) in PBS] for 3min, before rinsed with PBS twice. Sections were
stained in staining solution [1mg 5-bromo-4-chloro-3-indolyl β-D-galactoside (X-gal,
Sigma-Aldrich, St. Louis, MO), 40mM citric acid/sodium phosphate pH 6.0 (SigmaAldrich, St. Louis, MO), 5mM potassium ferrocyande (Sigma-Aldrich, St. Louis, MO),
5mM potassium ferricyanide (Sigma-Aldrich, St. Louis, MO), 150mM NaCl (SigmaAldrich, St. Louis, MO), 2mM MgCl2 (Sigma-Aldrich, St. Louis, MO)] for overnight at
37°C, before rinsed with PBS. Sections were then stained with eosin Y (Sigma-Aldrich,
St. Louis, MO).
6.10 STATISTICS
Statistical analysis was performed using Prism software (Graphpad Software, La
Jolla, CA). Values of p≤0.05 were considered statistically significant. Statistical
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significance is indicated by asterisks in figures: * for p values <0.05, ** for p values
<0.01, *** for p values <0.001, and **** for p values <0.0001.
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